Skip to main content
. Author manuscript; available in PMC: 2020 Mar 15.
Published in final edited form as: Clin Cancer Res. 2018 Dec 7;25(6):1889–1900. doi: 10.1158/1078-0432.CCR-18-2843

Figure 5. TAK-228 significantly reduced the growth rate of anal tumors in vivo.

Figure 5.

A. Graphic depiction of the change in tumor volume in NSG mice treated with TAK-228. Black-colored line indicates the control arm, while the red-colored line indicates treatment arm (TAK-228). B. Daily change of tumors’ volume in NSG mice. The double blue-colored asterisks indicate a significant reduction in tumorgraft growth rate in TAK-228 treated group compared to the control arm. C. Western blot analysis performed on lysates from tumorgrafts harvested at 0 hour, 3 hours and 24 hours post treatment with TAK-228. D. Representative sections of tumorgraft from both control arm and treatment arm were stained with Hematoxylin and Eosin (H&E, top panel) and Ki-67 immunohistochemistry (bottom panel). Brown stain indicated, positive DAB staining, while blue is the hematoxylin counterstain. Treatment with TAK-228 results in inhibition of tumor cell proliferation based on Ki-67 immunohistochemistry (bottom right panel).